This comes from a aite "prostatecancerinfolink." I have not investigated the "Dr" who made the comment so take it at face value.
OPKO Health, OURLab, and the 4Kscore test for prostate cancer risk
Posted on December 21, 2012 by Sitemaster
According to a media release on the company’s web site, OPKO Health has completed the acquisition of Prost-Data, Inc. (otherwise known to many prostate cancer patients and support group leaders – as well as their urologists — as Jonathon Oppenheimer’s independent uropathology company OURLab).
An earlier media release had stated that Dr. Oppenheimer would become the Chief Executive Officer of OPKO’s diagnostics division once the sale had been completed. Hopefully this acquisition will therefore have no negative effect on the quality of the prostate pathology services that Dr. Oppenheimer and his colleagues at OURLab have been providing to patients and their urologists for pretty much the past 15 years or so as a recognized uropathology services provider.
The acquisition of OURLab by OPKO Health is clearly associated with the impending introduction in the USA by OPKO of a new set of blood tests and an associated algorithm known as 4Kscore™. OPKO seems to believe that 4Kscore™ will be valuable in prediction of the probability of cancer-positive prostate biopsies. It is not clear (yet) to The “New” Prostate Cancer InfoLink exactly how accurate this test is or the degree to which it will be able to help to differentiate between men with clinically significant and men with indolent forms of prostate cancer.
The OPKO test panel will combine PSA data and data from two novel kallikrein markers and will supposedly provide significantly greater accuracy in estimation of risk for prostate cancer. The test panel appears to be based on markers used in the series of studies conducted by Hans Lilja, Andrew Vickers, and others in development of their data assessing risk for clinically significant prostate cancer over 25 and 30 years.
Filed under: Diagnosis, Risk Tagged: | 4Kscore, Diagnosis, kallikrein, OPKO, OurLab, PSA, risk, test
« Prognostic application of [11C]choline PET/CT scanning in selected patients New genetic mechanism explains prostate cancer progression in androgen-suppressed patients »
Dr. James Frazier, on December 21, 2012 at 11:27 pm said:
I have been floored by the presentations on this technology. This is going to help a lot of people and I can’t wait until it’s available in the USA.